Innov.Cell ended its successful participation in CPHI 2024
Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries. Some of our current distribution partners have joined us to show their commitment to continuing to do business with us and to share their testimony regarding the outstanding quality of our products.
This year's priority in our discussions during CPHI was KELO.CELL - the most innovative scar treatment option, KELO.CELL Biogel presents a unique formulation that combines silicone with stem cell extracts, providing a dual-action effect that effectively works on hydration and inflammation.
Developed by the well-known German company SanderStrothmann, it brings a unique approach to treating scars and is clinically tested and certified by Dermatest. KELO.CELL Biogel has two different presentations, 6g, and 15g, and we are pleased to announce the recent introduction of two new formulations: KELO.CELL Scar Concealer and KELO.CELL PSORIS Line, specially developed for psoriasis and atopic dermatitis-prone skin. The KELO.CELL PSORIS SOS Acute Balm provides an immediate relief of psoriasis itchiness, and irritation, while the KELO.CELL PSORIS Body Lotion is formulated to prevent further breakouts and extend the injury-free period. Designed to work together, this matching duo is a complete game-changer in addressing psoriasis and atopic dermatitis skin-associated symptoms.
Innov.Cell's objective is to assume market leadership in skin care, with a growing portfolio that will meet unmet needs for mechanical, traumatic, and chemical skin injuries, increasing from the current 2 to 4 lines of complementary products, already in 2025.
Innov.Cell Therapeutics seeks innovation leadership in skin care and wound healing.
-
Innov.Cell ended its successful participation in CPHI 2024
Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.
Read more -
OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)
Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
Read more